Guardant Health
Guardant Health, Inc., a leading precision oncology company, is headquartered in the United States, with significant operations across North America and Europe. Founded in 2012, the company has rapidly established itself in the biotechnology industry, focusing on non-invasive cancer detection and monitoring through advanced genomic testing. Guardant Health is renowned for its flagship product, the Guardant360® test, which provides comprehensive genomic profiling of solid tumours using a simple blood draw. This innovative approach allows for personalised treatment strategies, setting the company apart in the competitive landscape of cancer diagnostics. With a strong market position, Guardant Health has achieved notable milestones, including partnerships with major pharmaceutical companies and contributions to pivotal clinical trials. Its commitment to transforming cancer care through cutting-edge technology continues to drive its success in the oncology sector.
DitchCarbon Score
How does Guardant Health's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Guardant Health's score of 32 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Guardant Health's reported carbon emissions
In 2023, Guardant Health, headquartered in the United States, reported total carbon emissions of approximately 4,222,000 kg CO2e, comprising 1,659,000 kg CO2e from Scope 1 and 2,563,000 kg CO2e from Scope 2 emissions. The company has not disclosed any Scope 3 emissions data. Guardant Health is committed to significant reductions in its carbon footprint, aiming to reduce both Scope 1 and Scope 2 emissions to near zero by 2025. This commitment reflects the company's proactive approach to climate action within the pharmaceuticals, biotechnology, and life sciences sector. As of November 2023, Guardant Health has not yet committed to a net-zero target but has established near-term reduction goals, demonstrating its dedication to sustainability and environmental responsibility. The emissions data and reduction initiatives are sourced directly from Guardant Health, Inc., with no cascaded data from parent or related organisations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | |
|---|---|
| Scope 1 | 1,659,000 |
| Scope 2 | 2,563,000 |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Guardant Health is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
